Induction chemotherapy followed by radiotherapy for larynx preservation in advanced laryngeal and hypopharyngeal cancer: Outcome prediction after one cycle induction chemotherapy by a score based on clinical evaluation, computed tomography-based volumetry and 18F-FDG-PET/CT

Eur J Cancer. 2017 Feb:72:144-155. doi: 10.1016/j.ejca.2016.11.013. Epub 2016 Dec 26.

Abstract

Background: Long-term laryngectomy-free (LFS), tumour-specific (TSS) and overall survival (OS) is achieved by non-surgical larynx preservation (LP) only in a proportion of patients with locally advanced laryngeal or hypopharyngeal cancer. A score facilitating decision-making after 1 cycle induction chemotherapy (IC-1) may improve LFS and TSS.

Methods: Early response to IC-1 with TPF ± cetuximab was assessed in 52 patients using endoscopic tumour staging for selecting total laryngectomy for non-responders with endoscopic tumour surface shrinkage <30% versus induction chemotherapy plus radiotherapy (IC + RT) for responders. Computed tomography (CT)-based volumetry was used to assess volumes of primary tumour, neck nodes and their sum; maximum and mean standardised uptake value (SUVmax, SUVmean) were measured by 18F-FDG-PET/CT. Baseline and residual values after IC-1 were calculated and correlated with LFS, TSS and OS.

Results: After IC-1, 39/52 patients (75%) were early responders. Early response predicted complete response to IC + RT (p = 8.48 × 10-9). Early laryngectomised non-responders and responders with endoscopic tumour surface shrinkage > 70% had best OS. Significant independent predictors for LFS in responders are number of CT-staged suspect positive neck nodes (N+), residual primary tumour volume, residual total tumour volume and the ratio of residual SUVmax and SUVmean (resSUVmax/resSUVmean). Our LFS-score combines >2N+, residual primary tumour volume > 20%, residual total tumour volume > 5.6 mL and resSUVmax/resSUVmean > 1.51 weighted by their hazard ratio (12, 6, 5 and 4); LFS-score ≤ 16 predicts increased LFS, OS and TSS (p < 0.05).

Conclusion: LFS-score ≤ 16 identifies in responders to IC-1 the patients with maximum benefit of non-surgical LP achieving long-term LFS. Even more importantly, a LFS-score > 16 defines patients unsuitable for LP applying the TPF/TP IC + RT protocol.

Keywords: (18)F-FDG; Decision-making; Early response evaluation; HNSCC; Head and neck cancer; Hypopharyngeal cancer; Induction chemotherapy; Laryngeal cancer; Larynx preservation; PET/CT.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cetuximab / administration & dosage
  • Cisplatin / administration & dosage
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Hypopharyngeal Neoplasms* / drug therapy
  • Hypopharyngeal Neoplasms* / radiotherapy
  • Induction Chemotherapy / methods*
  • Laryngeal Neoplasms* / drug therapy
  • Laryngeal Neoplasms* / pathology
  • Laryngeal Neoplasms* / radiotherapy
  • Lymph Nodes / pathology
  • Male
  • Middle Aged
  • Organ Sparing Treatments / methods
  • Prospective Studies
  • Salvage Therapy / methods*
  • Survival Analysis
  • Taxoids / administration & dosage
  • Tomography, X-Ray Computed

Substances

  • Taxoids
  • Cetuximab
  • Cisplatin
  • Fluorouracil

Supplementary concepts

  • TPF protocol